Document Detail

Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
MedLine Citation:
PMID:  6421866     Owner:  NLM     Status:  MEDLINE    
Thyroidal suppressibility by exogenous T3 in terms of both radioiodine uptake (RAIU) and serum T4 was evaluated in 115 hyperthyroid patients treated with methimazole for 2 yr and followed for an additional 2 yr to study the rate of recurrence. Various other serum parameters including serum thyroglobulin concentrations, thyroid autoantibody, and TSH receptor antibody titers, and thyroidal responses to TRH-induced TSH elevation were also determined. After 2 yr of methimazole therapy, thyroidal RAIU was not suppressible (RAIU less than 12%/4 h was defined as suppressible) in 50 of 115 patients (group I). Of 65 patients with suppressible thyroid RAIU, serum T4 was significantly reduced (less than 60% of pre-T3 level) by T3 administration in only 43 patients (group III) but not in the remainder (group II). Antithyroid drug therapy was discontinued in the group II and III patients, and 7 of the patients had recurrence of hyperthyroidism within 2 yr of follow-up. All of them were from group II. The thyroidal response to TSH was greater in group III patients than in group II patients. During antithyroid drug therapy, decrease of microsomal antibody titer was more likely to occur in group III patients than in those of group II. Serum thyroglobulin concentrations were uniformly normal in treated patients irrespective of T3 suppressibility. TSH receptor antibody was positive in all 13 untreated patients with Graves' disease but was negative in treated patients regardless of their T3 suppressibility. Measurement of both thyroidal RAIU and serum T4 after administration of T3 improves the reliability of T3-suppression testing as a predictor of the remission of Graves' disease.
T Yamada; Y Koizumi; A Sato; K Hashizume; T Aizawa; N Takasu; H Nagata
Related Documents :
10397076 - Branched-chain amino acid therapy for spinocerebellar degeneration: a pilot clinical cr...
708096 - Neurological abnormalities in patients treated for hypothyroidism from early life.
9855346 - Optimal management of amiodarone therapy: efficacy and side effects.
7488816 - Frequency, clinical and laboratory features of thyroiditis in girls with turner's syndr...
25336486 - Transperineal sonographic anal sphincter complex evaluation in chronic anal fissures.
18831656 - Long-term outcomes and prognostic factors in pediatric patients with severe traumatic b...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  58     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  1984 Apr 
Date Detail:
Created Date:  1984-04-20     Completed Date:  1984-04-20     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  676-80     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Autoantibodies / metabolism
Evaluation Studies as Topic
Graves Disease / drug therapy*
Iodine Radioisotopes / diagnostic use
Methimazole / therapeutic use*
Middle Aged
Thyroglobulin / metabolism
Thyroid Function Tests / methods
Thyroid Gland / immunology,  metabolism
Thyrotropin / secretion
Thyrotropin-Releasing Hormone / diagnostic use
Thyroxine / blood
Triiodothyronine / diagnostic use*
Reg. No./Substance:
0/Autoantibodies; 0/Iodine Radioisotopes; 24305-27-9/Thyrotropin-Releasing Hormone; 60-56-0/Methimazole; 6893-02-3/Triiodothyronine; 7488-70-2/Thyroxine; 9002-71-5/Thyrotropin; 9010-34-8/Thyroglobulin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A competitive ligand binding assay for measurement of thyroid hormone-binding inhibitor in serum and...
Next Document:  Histamine-induced paradoxical growth hormone response to thyrotropin-releasing hormone in normal men...